Choosing the right angiotensin-receptor blocker for patients with diabetes: still controversial
- PMID: 23836856
- PMCID: PMC3761003
- DOI: 10.1503/cmaj.130507
Choosing the right angiotensin-receptor blocker for patients with diabetes: still controversial
Comment on
-
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.CMAJ. 2013 Sep 3;185(12):1035-41. doi: 10.1503/cmaj.121771. Epub 2013 Jul 8. CMAJ. 2013. PMID: 23836857 Free PMC article.
Similar articles
-
Antihypertensive treatments for adults with type 2 diabetes.BMJ. 2016 Feb 11;352:i560. doi: 10.1136/bmj.i560. BMJ. 2016. PMID: 26867645 No abstract available.
-
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.CMAJ. 2013 Sep 3;185(12):1035-41. doi: 10.1503/cmaj.121771. Epub 2013 Jul 8. CMAJ. 2013. PMID: 23836857 Free PMC article.
-
[Angiotensin II type-1 receptor antagonists and diabetes mellitus].Wien Med Wochenschr. 2001;151(7-8):165-8. Wien Med Wochenschr. 2001. PMID: 11450165 Review. German.
-
[ARB as a drug for diabetic microangiopathy].Nihon Rinsho. 2009 Apr;67(4):777-82. Nihon Rinsho. 2009. PMID: 19348242 Review. Japanese.
-
Vascular and Neural Complications in Type 2 Diabetic Rats: Improvement by Sacubitril/Valsartan Greater Than Valsartan Alone.Diabetes. 2018 Aug;67(8):1616-1626. doi: 10.2337/db18-0062. Epub 2018 Jun 25. Diabetes. 2018. PMID: 29941448
Cited by
-
comparative effectiveness research collaboration and precision medicine.Ann Neurosci. 2015 Jul;22(3):127-9. doi: 10.5214/ans.0972.7531.220301. Ann Neurosci. 2015. PMID: 26130919 Free PMC article. No abstract available.
References
-
- Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multi-factorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580–91 - PubMed
-
- Sjølie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008;372:1385–93 - PubMed
-
- ONTARGET Investigators Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547–59 - PubMed
-
- Ruschitzka F, Taddei S. Angiotensin-converting enzyme inhibitors: First-line agents in cardiovascular protection? Eur Heart J 2012;33:1996–8 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources